We studied the quality of life (QoL) in patients with multiple sclerosis (MS) with the SF-36 compared to the control groups and in terms of comorbidity, as well as to determine the correlation between QoL and the degree of disability, the level of severity of fatigue, depression, pain, disorders of cognitive functions. The study involved 205 MS patients with different forms of course and 157 people made up the control group. Evaluated the clinical and demographic characteristics of the patients with MS due to comorbidity, determines the level of disability (EDSS), severity of pain (VAS), the severity of fatigue (FSS), depression (BDI-II), cognitive impairment (MMSE), quality of life ( SF -36 One or more concomitant disease was detected in 102 (49.3%) patients with MS, there was no co-morbidities in 105 (50.7%) patients with MS. It has been found that in patients with MS I and II groups QoL were significantly lower compared with controls both the individual scales, and by generalized indicators. Also found that during the correlation analysis between QoL and data EDSS, FSS, BDI-II, VAS and MMSE in patients with MS I and II the closest correlations were observed between the indices of quality of life and EDSS, and the least close - between QoL and MMSE. The most informative in establishing correlations between QoL and data EDSS, FSS, BDI-II, VAS and MMSE in patients with MS I and II according to our information was the scale of VT and generalized indicators MH and PH, and the least informative - the scale of GH. Also, it was found that the maximum reduction of generalized QoL in patients with MS group II (relative to the average for the group II) was associated with policomorbidity.
2. Comparison of generic to disease-targeted health-related quality-of-life measures for multiple sclerosis/ Vickrey B.G., Hays R.D., Genovese B.J. [et al.]//J Clin Epidemiol.- 1997.- Vol.50.- Р.557–569.
3. Doctors and patients don’t agree: cross sectional study of patients’ and doctors’ perceptions and assessments of disability in multiple sclerosis/ Rothwell P.M., McDowell Z., Wong C.K. [et al.]// BMJ.- 1997.- Vol.314.- Р.1580–1583.
4. Donnellan C. P. Comparison of the effect of two types of acupuncture on quality of life in secondary progressive multiple sclerosis: a preliminary single- blind randomized controlled trial/ Donnellan C. P. , Sharley J. // Clinical Rehabilitation.- 2008.- Vol. 22.-№ 3.- Р.195–205.
5. Esmonde L. Complementary therapy use by persons with multiple sclerosis: benefits and research priorities/ Esmonde L., Long A. F.// Complementary Therapiesin Clinical Practice.- 2008.- Vol.14.- №. 3.- Р. 176–184.
6. Health-related quality of life in people with multiple sclerosis undergoing inpatient rehabilitation/ Freeman J.A., Langdon D.W., Hobart J.C. [et al.]// J Neurol Rehabil.- 1996.- Vol.10.- Р.185–194.
8. Monzon M. Quality of life in migraine and chronic daily headache patients/ Monzon M., Lainesz M. // Cephalagia.- 1998.- Vol.18.- Р.638–643.
9. Qualitativ ecomparison of the reliability of health status assessments with Euro Qol and SF-36 questionnaires after stroke/ Dorman P., Slattery J., Farrell B.[et al.]// Stroke.- 1998.- Vol.29.-Р.63–68.
10. Quality of life for veterans with multiple sclerosis on disease-modifying agents: Relationship to disability/ Guarnaccia J. B., Aslan К., O’Connor T. Z. [et al.]// Journal of Rehabilitation Research & Development.- 2006.- №1.- Vol.43.- P. 35–44.
11. Quality of life in people with multiple sclerosis: data from the Sonya Slifka Longitudinal Multiple Sclerosis Study / Wu N., Minden S.L., Hoaglin D. [et al.]// Journal of Health and Human Services Administration. 2007.- Vol.30.- Р.233–267.
12. Self-reported functioning and well-being in patients with Parkinson’s disease:comparison of the shortform health survey (SF-36) and the Parkinson’s disease questionnaire (PDQ-39)/ Jenkinson C., Peto V., Fitzpatrick R. [et al.]// Age Ageing.- 1995.- Vol.24.- Р.505–509.
13. Stewart A.L. The MOS short-form general health survey: reliability and validity in a patient population/ Stewart A.L., Hays R.D., Ware J. J.// Med Care.- 1988.- Vol.26. – Р.724–735.
14. The ALS health profile study: quality of life of ALS patients and carers in Europe/ Jenkinson C., Fitzpatrick R., Swash M. [et al.]// J Neurol 2000.- Vol. 247.-Р.835–840.
15. The Canadian Burden of Illness Study Group. Burden of illness of multiple sclerosis: part II: quality of life./ Can J Neurol Sci.- 1998.- Vol.25. – Р.31–38.
16. The SF-36 as a health status measure for epilepsy: a psychometric analysis/ Jacoby A., Baker G., Steen N. [et al.]// Qual Life Res.- 1999.- Vol.8.- Р.351–364.
17. The SF-36 in multiple sclerosis: why basic assumptions must be tested/ Hobart J., Freeman J., Lamping D. [et al.]// J Neurol Neurosurg Psychiatry.- 2001.- Vol.71. –Р.363–370.
18. Use of therapies other than disease-modifying agents, including complementary and alternative medicine, by patients with multiple sclerosis: a survey study/ Stoll S. S., Nieves C.,. Tabby D. S. [et al.]// Journal of the American Osteopathic Association.- 2012.- Vol. 112.- № 1.- Р. 22–28.
19. Ware J.E.The MOS 36-Item Short-Form Health Survey (SF-36). I.Conceptual framework and item selection/ Ware J.E., Sherbourne C.D. // Med Care. - 1992.- Vol. 30. – Р. 473-483.
This work is licensed under a Creative Commons Attribution 4.0 International License.